SOX2 and glioblastoma: When cases were separated into high or low percentage of SOX2-expressing GBM (above or below 50% of nuclei positive on average for the case), the mean variation was 48% for samples in cases with a low percentage of SOX2-positive cells, and 26.6% in high-expressing cases (p < 0.0005).